Business in Brief: Teva Shares Drop After Rival Reports Progress on Alternative Multiple Sclerosis Drug

Shares of Teva Pharmaceuticals fall after a company develops a competitor to the Copaxone multiple sclerosis drug ■ IceCure Medical received approval to use extreme cold to destroy tumors ■ Tel Aviv shares ended lower for a third day

comments Print
Teva shares drop after rival reports progress of Copaxone alternative